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Polyurea dendrimer for efficient cytosolic siRNA 
delivery 
Rita B. Restani,a João Conde,b,c,d  Pedro V. Baptista,b Maria Teresa Cidade,e Ana 
M. Bragança,f Jorge Morgado,f,g Ilídio J. Correia,h Ana Aguiar-Ricardo a,* and 
Vasco D. B. Bonifácio f,*  
The design of small interfering RNA (siRNA) delivery materials showing efficacy in vivo is at the 
forefront of nanotherapeutics research. Polyurea (PURE-type) dendrimers, are ‘smart’ biocompatible 3D 
polymers that unveil a dynamic and elegant back-folding mechanism involving hydrogen bonding 
between primary amines at the surface and tertiary amines and ureas at the core. Similarly to a 
biological proton pump, they are able to automatically and reversibly rework their conformation in 
response to pH stimulus. Herein, we show that PURE-G4 is an useful gene silencing platform showing no 
cellular toxicity. As a proof-of-concept we investigated the PURE-G4-siRNA dendriplex, which showed 
to be an attractive platform with high transfection efficacy. The simplicity associated to the 
complexation of siRNA with polyurea dendrimers makes them a powerful tool for efficient cytosolic 
siRNA delivery. 
1. Introduction 
Among anticancer agents, siRNA has emerged as a powerful 
tool to block gene function via sequence-specific post-
transcriptional gene silencing.1-3 To reach the cytoplasm and 
interact with the RNAi machinery, naked siRNA need to 
transpose several physiological barriers since they are highly 
hydrophilic to cross the cell membrane, show poor chemical 
stability and low protection against serum nucleases leading to 
low blood plasma half-life circulation.4-6 Over the last two 
decades numerous polymeric and lipophilic vectors had been 
developed, yet only a small fraction prospered to clinical trials7 
and none of these vectors have received FDA approval.8 
The unique 3D architecture of dendrimers renders these 
polymers remarkable structures for enhanced solubilization and 
controlled release of molecular guests. As a consequence of its 
unimolecular structure, in cases where dendritic motifs are 
capable of hydrogen bonding, both shell and core can assume a 
restricted mobility where the system guest-in-box9 shows 
efficient applications in Nanomedicine.10-14 Despite being the 
most described dendrimer structures in the literature, 
poly(amido amine) (PAMAM-type) amine-terminated 
dendrimers have been reported to exhibit cytotoxicity as a 
consequence of positive charged surface. Remarkably, we 
recently reported that polyurea (PURE-type) amine-terminated 
dendrimers15 are non-cytotoxic, biodegradable, biocompatible,  
fluorescent and have high transfection efficiency in human 
fibroblasts, showing cytoplasmic distribution. Although charge 
is undoubtedly a general parameter associated with 
cytotoxicity, several other properties including charge density, 
morphology, biodegradability, flexibility, molecular weight and 
amphipathic character are likely relevant to dictate 
biocompatibility.16,17 Herein, we scrutinized the chemistry of 
PURE-type dendrimers in order to fully understand the factors 
governing self-assembly processes upon different stimuli so as 
to understand their potential for intracellular trafficking, thus 
providing a strategy for efficient cellular uptake and subsequent 
enhancement of lysosomal/endosomal siRNA escape. 
 
2. Results and discussion 
The intramolecular back-folding in different dendrimer systems 
is well described in literature.18-22 Regarding PAMAM 
dendrimers, theoretical23 and experimental data using pH24 and 
1H NMR25,26 studies support a solvent-dependent 
“conformational dance”.  
In the case of PURE dendrimers a more effective 
intramolecular back-folding is expected due to the strength of 
urea hydrogen bonding. Indeed, their IR spectra15 suggest a 
rigid well-organized core structure due to bidentate hydrogen 
bonding between urea motifs (1638-1644 cm-1) and absence of 
free urea carbonyl groups (ca. 1690 cm-1). A similar analysis of 
urea N-H stretching modes also supports that the observed 
hydrogen bonding correlates well with bidentate arrangements 
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(3332-3347 cm-1) without free N-H urea groups (ca. 3450 cm-
1).27,28 
Considering the challenges before reaching the target, it is 
mandatory to explore the multi physico-chemical properties of 
the carriers in aqueous solution by mimicking the cell and 
endosomal environment, thus providing relevant insights into 
drug delivery events. Therefore, we systematically studied the 
behavior of PURE-type dendrimers at various protonation 
levels. To predict the intramolecular behaviour upon different 
pH values, the 1H NMR spectrum of the fourth generation 
polyurea dendrimer (PURE-G4) was acquired in D2O (pH 
11.55) and the solution was then acidified with DCl (pH 1.77), 
and finally brought to the initial pH using NaOD (Fig. 1).  
The aqueous solutions of PURE dendrimers are strongly basic 
due to the high content of tertiary amines in the backbone. The 
spectra show that a reversible protonation process occurs upon 
acidification-basification (Fig. 1A and 1B), revealing that the 
medium pH strongly impacts the dendrimers conformation. The 
ethylene protons from the tertiary amine core showed a very 
large downfield shift (∆δ= 0.90 ppm), and are the most affected 
upon protonation (Fig. 1, a and a’) when compared with the 
ethylene protons near the urea groups (Fig. 1, b and b’), which 





















H NMR titration of the PURE-G4 dendrimer: PURE-G4 spectra in D2O and 
after addition of NaOD (A), and after addition of DCl (B). The chemical structure 
of protonated PURE-G4, with the attributed chemical shifts (a’ and b’) in 
spectrum B, is shown at the top. Chemical shifts of protons a and b in spectrum A 
correspond to neutral PURE-G4 species. 
Atomic force microscopy (AFM) was used to study 
morphology and film properties.29 For film preparation, two 
concentrations (17.5 and 8.5 nM) and two methods (spin-
coating and dropcast) were used, and best results were obtained 
by dropcast in mica plates using 8.35 nM aqueous solutions 
(pH 7). Although AFM images show equivalent noise, irregular 
aggregates of ~20 nm were observed (Supporting Information, 
Fig. S1). The low resolution and aggregation factor did not 
allow further assessment concerning changes to dendrimer size 
with pH. Further dimensional characterization and evaluation of 
pH influence on morphology was investigated via Dynamic 
Light Scattering (DLS) at different pHs. However, no 
reproducible results were obtained for aqueous solutions with  
dendrimer concentrations in the range 1-100 mg/mL, which 
precluded further analysis, due to the formation of aggregates. 
The degree of protonation was determined by titration and the 
values of pKa1= 4.98 and pKa2= 9.78 for tertiary and primary 
amines, respectively, were obtained (Fig. S2A). The isoelectric 
point was found at pH 6.62 (Fig. S2). These pH-dependent 
conformations, owed to protonation and urea-assisted 
neutralization events, are characteristic of polyurea dendrimers 
and are schematically represented in Fig. 2. This protonation 
mechanism resembles proteins ‘unfolding’ in response to the 




Fig. 2. Schematic representation of the PURE dendritic system at different 
protonation levels. 
 
As expected, the rheological properties are highly dependent on 
the capability to establish intramolecular interactions through 
hydrogen bonding. Fig. S3 in Supporting Information shows 
that an increase on temperature causes a decrease of dendrimer 
viscosity, suggesting that intramolecular H-bonds are partially 
weakened reducing friction between neighbouring molecules, 
and consequently the viscosity. This supports the observed hd 
differences at 25 and 37 ºC, 3.41 and 5.61 nm, respectively. 
Data also showed that (highly basic) PURE-type dendrimers 
hold a cationic nature (Fig. 3A), confirming that PURE-G4 has 
a higher electrophoretic mobility than PAMAM-G4 amine-
terminated dendrimer, which can translate the lower Mw of the 
former. Taken together, the cationic surface of the dendritic 
system, the pH-dependent flexible structure and the high 
buffering capacity in the pH range of the endosome, we 
propose that PURE-G4 present ideal features as a siRNA 
delivery platform.31 It is well known that cationic dendrimers 
can complex with DNA or RNA (i.e. siRNA) via electrostatic 
interactions.32,33 We envisaged that electrostatic interactions 
between the positively charged terminal amines from polyurea 
dendrimers and the negatively charged siRNA phosphate 
groups could easily be established. Consequently, an 
electrophoretic mobility shift assay (EMSA) was performed on 
agarose gel using increasing concentrations of PURE-G4 (1, 
2.5, 5 and 7.5 mg/mL), previously incubated with 10 µM of 
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siRNA, Fig. 3B and 3C. The relative electrophoretic mobility 
(RF) for PURE-G4 complexed with siRNA (polyurea 
dendriplexes) clearly demonstrate that as the mass of PURE-G4 
increases, retardation in electrophoretic mobility of siRNA 
occurs, suggesting successful complexation between both (Fig. 





Fig. 3. Photographs of EMSA gel after electrophoresis of PAMAM and PURE-G4 
dendrimers (A) and increasing amounts of PURE-G4 complexed with 10 µM of 
siRNA (B, C). Determination of the mobility (RF) values for dendriplexes (D). RF= 
distance migrated/gel length. Graph shows electrophoretic mobility in function 
of PURE-G4 concentration. 
 
To evaluate cell toxicity of the dendriplexes, we assessed cell 
survival rates of HepG2 cells via the [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazoliumbromide] (MTT) reduction assay. 
PURE-G4 (1, 2.5, 5 and 7.5 mg/mL) and dendriplexes 
(prepared from the incubation of 1, 2.5, 5 and 7.5 mg/mL of 
PURE-G4 with 10 nM of siRNA) were used. PURE-G4 showed 
a reduction in cell viability upon 2.5 mg/mL. Contrarily to what 
was observed for PURE-G4, no cell cytotoxicity was detected 
up to 48 h incubation with polyurea dendriplexes even at high 
PURE-G4 concentrations (Fig. 4A), clearly demonstrating the 
biological benefits of such complexation. The great differences 
on the toxicity may be justified based on the charge 
neutralization resultant from the complexation between the 
negatively charge backbone from siRNA phosphate groups and 
positively charged PURE-G4. These findings are in agreement 
with the neutral zeta potential value obtained for the complex 
(1.4 ± 0.3). Comparison between cell viability of PURE-G4 and 
PURE-G4-siRNA complexes and the commercial delivery 
vector Lipofectamine can be found in Supporting Information, 
Fig. S4.  
Regarding oxidative stress, the glutathione-S-transferase (GST) 
activity assay showed that PURE-G4 caused extensive 
glutathione depletion, thus extensive oxidative damage. This 
behavior was observed as from 2.5 mg/mL of PURE-G4 
resulting in ~30%, 50% and 75% reduction in GST activity, 
respectively (Fig. 4B). MTT and GST activity assay, however, 
revealed that PURE-type dendriplexes are highly biocompatible 




Fig. 4. Cytotoxicity via the MTT assay (A) and oxidative stress through the GST 
activity assay (B) of PURE-G4 (1, 2.5, 5 and 7.5 mg/mL) and PURE-G4 complexed 
with siRNA (1, 2.5, 5 and 7.5 mg/mL of dendrimer pre-incubated with 10 µM of 
siRNA) administered to human hepatocellular liver carcinoma cells (HepG2) at 48 
hours of exposure (*, P<0.05; **, P <0.001). 
The ‘smart’ behavior of polyurea  dendrimers, basically 
governed by their ability to establish reversible hydrogen 
bonding as an adaptation to stimuli, disclosed a strategic 
conformational performance for a conceivable efficient 
sequestration of the polyurea dendriplex system (Fig. 5A) into 




Fig. 5. Schematic representation of PURE-G4 and siRNA complexation in solution 
(A); Endocytosis (B); Endosome acidification due to proton sponge effect (C) 
followed by endosome swelling (D); membrane disruption (E) and siRNA loading 
into RISC (F) for gene silencing. RISC= RNA interference silencing complex.  
The acquired results lead us to believe, that as claimed in 
literature,34,35  the cocktail of amines (primary and tertiary) and 
ureas present in the same nano-vehicle may be able to buffer 
the acidic environment within the endosome. As such, to re-
establish the endosomal environment a titrable process is likely 
to occur, mainly due to a “proton sponge” mechanism,36,37 in 
order to lower the cells pH. At pH 5, the buffering capacity of 
the carrier system (Fig. 5C) will induce the proton sponge 
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effect and induce swelling of the dendrimer with concomitant 
endosomal disruption (Fig. 5D and 5E). These events would 
cause the dendriplex to be released in the reductive 
environment of the cytosol where siRNA can be easily cleaved 
into the cytosol, allowing for incorporation into the RNAi 
pathway (e.g. RISC incorporation),38 Fig. 5F, that subsequently 
promote specific events that trigger silencing of specific 
genes.39,40 
To track the intracellular co-localization of PURE-G4 and 
PURE-G4-siRNA within lysosomes we took profit from the 
intrinsic fluorescence of PURE-type dendrimers. In order to 
check dendrimers internalization into the lysosomes we used 
Lysotracker® Green to label these structures. Confocal 
microscopy exposed dendrimers entrapment within the 
lysosomal vesicles (see Fig. 6). 
 
 
Fig. 6. Intracellular co-localization of PURE-G4 (A) and PURE-G4-siRNA (B) within 
lysosomes. HepG2 cells were treated with 1mg/mL of PURE-G4 and PURE-G4-
siRNA dendrimers (in red) for 48 hours. Lysosomes (in green) were stained with 
Lysotracker® Green DND26. Overlap of dendrimers and lysosome trackers are 
represented in yellow in the merged images. 
 
In detail, the co-localization of the tested dendrimers (red dots) 
within lysosomes (green dots), produced a yellow fluorescence 
in the merged images, Fig. 6A and 6B. The discrete punctuate 
appearance of the dendrimer fluorescence and the co-
localization of the dendrimer within the lysosome-specific dye 
insinuated the significant dendrimer uptake into the lysosomes. 
However, higher internalization efficiency into the lysosome 
compartment was observed for the free formulation PURE-G4, 
which has higher hydrophobic character. The PURE-G4-siRNA 
seemed to escape lysosome more efficiently. 
As proof-of-concept, the in vitro potential of the polyurea 
dendriplex platform was evaluated using HepG2 cells 
transfected with GFP that was then targeted for silencing with 
anti-GFP siRNA−PURE-G4 dendriplexes. Cells were treated 
with several siRNA/PURE-G4 ratios by incubation of different 
concentrations of PURE-G4 (1, 2.5, 5 and 7.5 mg/mL) with 10 
µM of siRNA control or anti-GFP siRNA. After 48 hours, GFP 
fluorescence of cells treated with anti-GFP dendriplexes was 
analyzed (Fig. 7) by comparing it with the control (Fig. 7A) 




Fig. 7. Representative series of epi-fluorecence images of human hepatocellular 
liver carcinoma cells (HepG2), 48 hours after incubation with PURE-G4-siRNA 
dendriplexes (1, 2.5, 5 and 7.5 mg/mL of dendrimer pre-incubated with 10 µM of 
siRNA control) (A) or anti-GFP siRNA (B). The series of images represents the 
green fluorescence channels corresponding to GFP fluorescence and the blue 
fluorescence channels corresponding to PURE-G4 dendriplexes. Scale bars = 20 
µm. 
The blue fluorescence pattern observed confirmed the PURE-
G4 input into the cells and their distribution mainly into the 
cytoplasm. Concerning GFP fluorescence, it was visually clear 
that the PURE-type dendriplex induced specific GFP 
knockdown with an inhibition efficacy of ca. 63% (Fig. 7B), 
when compared to control siRNA, indicating that the 
knockdown is sequence specific.  
The quantification of GFP expression levels for each 
formulation is shown in Fig. 8. GFP silencing was confirmed 
by significant fluorescence decrease from protein in bulk cell 
lysates (as percentage of original GFP fluorescence levels) only 
in cells treated with anti-GFP PURE-G4-siRNA dendriplexes 
(7.5 mg/mL), when compared to control PURE-G4-siRNA 
dendriplexes and cells with no treatment. A silencing of 
approximately 80% was achieved for the PURE-type 
dendriplex, when compared to control siRNA (Fig. 8A). 
Similar results were achieved for mRNA levels of GFP, using 
Real-Time RT-PCR (Fig. 8B). Detailed information on primer 
sequence, cycling conditions and melting analysis about GFP 
expression assay can be found elsewhere.41 As for protein level, 
the mRNA expression reveals an approximately 75% 
knockdown of GFP with anti-GFP PURE-G4-siRNA 
dendriplexes (7.5 mg/mL), when compared to control PURE-
G4-siRNA dendriplexes. These data discloses that the PURE-
G4 siRNA dendriplexes are far more efficient that the 
commercially transfection agent, Lipofectamine. Using the 
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recommended Lipofectamine concentration for siRNA 
delivery, we could only achieve ~40% silencing of GFP in the 





Fig. 8. Quantification of GFP expression levels, 48 hours after incubation with 
PURE-G4-siRNA dendriplexes (1, 2.5, 5 and 7.5 mg/mL of dendrimer pre-
incubated with 10 µM of siRNA control). (A) At the protein level, a knockdown of 
approximately 80% was achieved for the PURE-type dendriplex, when compared 
to control siRNA. All GFP expression data was normalized to total protein 
quantification. (B) At the mRNA level, Real-Time RT-PCR results confirmed GFP 
knockdown after treatment with increasing amounts of anti-GFP PURE-G4-siRNA 
and control PURE-G4-siRNA dendriplexes using β-actin as reference. 
3. Conclusions 
In summary, we report the physical and chemical behavior of 
PURE-type dendrimers, a class of biocompatible and pH-
dependent fluorescent dendrimers that can be used as an 
efficient platform for siRNA delivery. The intelligent skilled 
biomimetic material showed the ability to change its 
conformation via a dynamic back-folding mechanism in 
response to external pH. Their ability to cross the cell 
membrane was clarified and their action as nano-buffers in the 
endosome proposed. Our results indicate that PURE-G4 
dendrimers compact and effectively deliver siRNA molecules 
into cells and can efficiently shutdown the expression of a 
specific gene. Moreover, the PURE-G4-siRNA dendriplex 
dramatically decline cell oxidative stress and cytotoxicity of the 
carrier system even at high concentrations when compared with 
PURE-G4. The absence of cytotoxicity combined with the high 
siRNA transfection efficiency and effective gene silencing 
capability may be explored as new gene delivery vectors for 
nano-therapeutics. In vivo studies are being developed in order 




PURE-type dendrimers were synthesized in supercritical carbon 
dioxide as previously reported15 using an adapted a high-
pressure apparatus.42,43 All reagents were purchased 




NMR experiments. The NMR spectra were recorded on Bruker 
ARX 400 MHz equipment. 1H NMR chemical shifts are 
reported as δ (ppm= parts per million) relative to the residual 
solvent peak.  
Dynamic Light Scattering. For particle size determination 
samples were analyzed through Dynamic Light Scattering - a 
nanoparticle analyzer from Horiba Scientific Nano Portica sz 
100 at an angle of 90º and at 37 ºC. Samples with 
concentrations in the range 1-100 mg/mL were previously 
filtered through a 0.45 µm membrane.  Diluted HCl solutions 
were used to study the pH influence on the particles size. The 
zeta potential of the dendriplex was measured at pH 7.4 using a 
concentration of 14 mg/mL. 
Atomic Force Microscopy. AFM was performed on a Molecular 
Imaging Agilent (model 5100) system operating in non-contact 
mode. Silicon cantilevers having a constant force in the range 
of 1-5 N/m and a resonant frequency ranging between 50-70 
kHz were used. All images were recorded with 256×256 pixels 
resolution. The AFM images were processed using second 
order plane fitting and second order flattens routines. The 
levelling routines were applied in order to remove the z offset 
between scan lines and the tilt and bow in each scan line. All 
AFM images were processed using the same levelling 
procedure with the final images indicating a flat planar profile. 
Gwyddion (version 2.25) software was used to process the 
AFM images.  
Potentiometric titration. Potentiometric titrations were 
performed using a Crison Basic 20 pH meter and a Crison 52 
09 pH electrode at room temperature (24 ± 0.1 ºC). 0.1 M NaCl 
solutions containing 3 mg/mL of PURE-G4 dendrimers were 
titrated by standard HCl (0.1 N).   
UV-Vis spectroscopy. The UV-Vis spectra of the titrated 
samples were obtained in a UV-1700 PharmaSpec 
Spectrometer from Shimadzu with a scan rate of 300 nm/min at 
25 ºC. 
Rheological measurements. The rheological measurements 
were performed on a Bohlin Gemini HRnano rotational 
rheometer (Malvern Instruments, UK) at different temperatures 
using a cone/plate geometry of 1º, 20 mm. Steady state 
measurements were performed in a shear rate range of 1-1000 s-
1. 
Agarose gel electrophoresis. 5 µL of loading dye (6×) were 
added to 15 µL of a PAMAM and PURE-G4 solution with a 
concentration of 14 mg/mL, and 12 µL of each sample were 
loaded onto a 2% agarose gel. Electrophorese was performed in 
Tris-Borate-EDTA (TBE) buffer (1×) at pH 8 (TBE buffer 
contains 89 mM Tris-base, 200 mM boric acid and 2 mM 
EDTA) at room temperature and 70 V for 30 min.  
Polyurea dendriplexes preparation. Increasing amounts of 
polyurea dendrimer (0.01 to 7.5 mg/mL) were mixed with 10 
nM of siRNA (Sense strand: 5’-
GCAUGACCAACAAGAUGAAUU-3’, Antisense strand: 3’-
UUCAUCUUGUUGGUCAUGCUU-5’; Dharmacon, Thermo 
Scientific) in DEPC-treated water, and incubated at 37 ºC for 2 
hours. Polyurea dendriplexes were then analyzed by 
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electrophoresis on a 2% (w/v) agarose gel (UltraPure™ 
Agarose, Invitrogen). 
Gel electrophoresis mobility shift assays (EMSA). Agarose gels 
were prepared in Tris-Borate-EDTA (TBE) buffer (1×) at pH 8 
(TBE buffer contains 89 mM Tris-base, 200 mM boric acid and 
2 mM EDTA). GelRed (Biotium) was added at 5× of a stock 
solution of 10.000× in water. Suitable sized wells (50 µL), were 
formed by placing a comb in the center of the gel. After the 
formation of PURE-G4-siRNA dendriplexes, 5 µL of loading 
dye (10 mM Tris-HCl pH 7.6, 0.03% bromophenol blue, 0.03% 
xylene cyanol FF, 60% glycerol, 60 mM EDTA; Fermentas) 
was added to ensure proper well loading and a constant electric 
field (70 V) was applied for 45 min for sufficient separation, at 
room temperature. EMSA gels after electrophoresis were 
visualized under UV illumination and gel photographs were 
taken with a Gel Documentation EQ System (Biorad). The 
electrophoretic mobility (RF) values for PURE-G4 complexed 
with siRNA were determined as follows: RF= distance 
migrated/gel length. 
Cell culture and dendrimer incubation. HepG2 cells (Human 
hepatocellular liver carcinoma cell line) were grown in 
Dulbecco's modified Eagle's medium with Glutamax (DMEM, 
Invitrogen) with 10% heat inactivated fetal bovine serum 
(Invitrogen), 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen) and maintained at 37 ºC in 5% CO2. Cells were 
also supplemented with 1× non-essential aminoacids (Sigma). 
Cells were seeded at a density of 1×105 cells/well in 24-well 
plates and grown for 24 h prior to transfection of the GFP 
vector (pVisionGFP-N vector 4.7 kb, Biovision) encoding for 
green fluorescent protein, VisionGFP, optimized for high 
expression in mammalian cells. On the day of transfection, 
EGFP vector (1 mg per well) was added to cells at 
approximately 50% confluence with 2 mg of Lipofectamine 
2000® (Invitrogen) and Opti-MEM® Reduced Serum Medium 
(Invitrogen) according to the manufacturer’s recommendations. 
On the day of dendrimer incubation, PURE-G4/siRNA 
complexes for 1, 2.5, 5 and 7.5 mg/mL of dendrimer pre-
incubated with 10 µM of siRNA control or anti-GFP siRNA 
were added to cells (for 48 hours) that were at approximately 
50% confluence. For comparison with dendriplex potency in 
silencing, Lipofectamine 2000® was also used to transfect anti-
GFP and control siRNAs. Briefly, after 24 h of GFP 
transfection, cells were treated with 10 µM anti-GFP and 
control siRNAs using 1.5 mg of Lipofectamine 2000® 
(Invitrogen) and Opti-MEM® Reduced Serum Medium 
(Invitrogen) according to the manufacturer’s recommendations. 
GFP silencing was evaluated at the protein level by measuring 
GFP fluorescence from cell lysates. Briefly, after 48 h, cells 
were washed with 1× PBS, lysed in water and collected for 
analysis of GFP silencing. Fluorescence was measured at least 
3 times in a Cary Eclipse spectrofluorimeter (Varian) using an 
Ultra-Micro quartz cell (Hëllma) by taking the area under the 
curve from 495 to 650 nm. GFP fluorescence values were 
normalized to the bulk protein concentration determined via the 
Bradford assay (Thermo Scientific), and then normalized 
against the controls to determine percent knockdown of GFP. 
At the mRNA level, GFP expression was measured using Real-
Time RT-PCR as described below. 
Real-Time RT-PCR. Total RNA was extracted from the cell line 
using the Trisure reagent (Bioline) according to the 
manufacturer’s protocol, and used for qRT-PCR to evaluate 
expression of GFP and β-actin. cDNA was attained by 
subjecting 1 µg of total RNA to Reverse Trancriptase with 
200U of Revert-AidTM M-MuLV Reverse Transcriptase 
(Fermentas) according to the manufacturer’s specifications, 
using 20 µM of GFP and β-actin reverse primers, annealing at 
42 ºC for 1 h and 70 ºC for 10 min to reverse transcriptase 
inactivation. Real-Time PCR amplification was performed in a 
Corbett Research Rotor-Gene RG3000 using SYBR GreenER 
Real-Time PCR Kit (Invitrogen) according to manufacturer’s 
specifications in 50 µl reactions containing 2 µl of cDNA, 1 × 
SYBR Green SuperMix and 200 nM of primers (STABVIDA, 
Portugal). 
Confocal microscopy. All confocal microscopy samples were 
prepared as described above. During the final 45 minutes of the 
incubations, the lysosomal dye Lysotracker® Green DND26 
(Invitrogen) was included at a final concentration of 62.5 nM. 
Cells were then fixed with 4% paraformaldehyde in 1× PBS for 
15 min at 37 ºC and incubated with 50 mM NH4Cl (that serves 
as uncoupler for blocking of free aldehyde groups and 
consequently quenching auto-fluorescence) for 15 min at 37 ºC. 
Finally, cells were mounted in glycerol 87%. Images of cells 
were taken with a Confocal Laser Point-Scanning Microscope 
Zeiss LSM 510 META. Once optimized, the same microscope 
settings were used throughout. For excitation laser lines were 
used at a wavelength of 405 nm for the dendrimers and 514 nm 
for Lysotracker®. 
Statistical analysis. All statistical analysis were performed with 
SPSS statistical package (version 17, SPSS Inc., Chicago, IL) 
using a Paired-Sample T-test. All experiments, unless otherwise 
stated, were performed in triplicate. All error bars used in this 
report are ± s.d. of at least three independent experiments. 
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